Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Nov 25, 2025 9:25 AM Eastern Standard Time Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence Share Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion†or the "Company†) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today anno ...